Jeffrey W. Albers, a director at $SYRE, sold 10,000 shares of the company on 08-07-2026 for an estimated $1,046,800. We received data on the trade from a recent SEC filing. This was a sale of approximately 51.7% of their shares of this class of stock. Following this trade, they now own 9,360 shares of this class of $SYRE stock.
$SYRE Insider Trading Activity
$SYRE insiders have traded $SYRE stock on the open market 52 times in the past 6 months. Of those trades, 0 have been purchases and 52 have been sales.
Here’s a breakdown of recent trading of $SYRE stock by insiders over the last 6 months:
- FUNDS MANAGEMENT LLC FAIRMOUNT sold 4,684,781 shares for an estimated $399,658,667
- SHELDON SLOAN (Chief Medical Officer) has made 0 purchases and 11 sales selling 102,958 shares for an estimated $7,354,471.
- CAMERON TURTLE (Chief Executive Officer) has made 0 purchases and 21 sales selling 90,000 shares for an estimated $6,247,822.
- SCOTT L BURROWS (Chief Financial Officer) has made 0 purchases and 15 sales selling 60,000 shares for an estimated $4,578,568.
- JEFFREY W. ALBERS has made 0 purchases and 3 sales selling 23,000 shares for an estimated $2,404,190.
- MICHAEL THOMAS HENDERSON sold 20,000 shares for an estimated $2,000,000
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$SYRE Hedge Fund Activity
We have seen 123 institutional investors add shares of $SYRE stock to their portfolio, and 57 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CAPITAL INTERNATIONAL INVESTORS removed 1,746,412 shares (-50.0%) from their portfolio in Q1 2026, for an estimated $88,089,021
- BLACKROCK, INC. added 985,384 shares (+17.8%) to their portfolio in Q2 2026, for an estimated $87,482,391
- CALIGAN PARTNERS LP added 878,127 shares (+inf%) to their portfolio in Q1 2026, for an estimated $44,292,725
- BANK OF AMERICA CORP /DE/ added 808,366 shares (+192.6%) to their portfolio in Q1 2026, for an estimated $40,773,981
- POINT72 ASSET MANAGEMENT, L.P. removed 662,351 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $33,408,984
- PARADIGM BIOCAPITAL ADVISORS LP added 490,000 shares (+33.4%) to their portfolio in Q1 2026, for an estimated $24,715,600
- COMMODORE CAPITAL LP removed 475,865 shares (-19.9%) from their portfolio in Q1 2026, for an estimated $24,002,630
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$SYRE Analyst Ratings
Wall Street analysts have issued reports on $SYRE in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Deutsche Bank issued a "Buy" rating on 06/04/2026
To track analyst ratings and price targets for $SYRE, check out Quiver Quantitative's $SYRE forecast page.
$SYRE Price Targets
Multiple analysts have issued price targets for $SYRE recently. We have seen 11 analysts offer price targets for $SYRE in the last 6 months, with a median target of $95.0.
Here are some recent targets:
- David Hoang from Deutsche Bank set a target price of $135.0 on 06/23/2026
- Julian Harrison from BTIG set a target price of $112.0 on 06/15/2026
- Alex Thompson from Stifel set a target price of $107.0 on 05/06/2026
- Samantha Semenkow from Citigroup set a target price of $97.0 on 05/06/2026
- Debanjana Chatterjee from Jones Trading set a target price of $95.0 on 04/17/2026
- Yanan Zhu from Wells Fargo set a target price of $90.0 on 04/14/2026
- David Nierengarten from Wedbush set a target price of $80.0 on 04/14/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
